Ojeda Soledad, Anguita Manuel, Delgado Mónica, Atienza Felipe, Rus Carmen, Granados Amador L, Ridocci Federico, Vallés Federico, Velasco Jose A
Department of Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Eur J Heart Fail. 2005 Aug;7(5):921-6. doi: 10.1016/j.ejheart.2005.05.009.
The objective of the study was to evaluate whether improvements obtained during an intervention programme were maintained after the programme was stopped. 153 patients discharged with a diagnosis of heart failure (HF) were randomized to either usual care or an intervention programme, which included patient education, consultation with the cardiologist and monitoring in the Heart Failure Unit. After an average period of 16+/-8 months, the intervention programme was stopped. One year later, all the patients were re-examined to assess HF readmissions, all-cause mortality, quality of life, and prescribed medical treatment. During the 16+/-8-month treatment period, patients in the intervention group had a lower rate of HF readmissions (17% vs. 51%, p<0.01), less all-cause mortality (13% vs. 27%, p=0.03), improvement in quality of life (1.5+/-0.8 vs. 1.9+/-1, p=0.03) and optimisation of medical treatment was achieved. One year after stopping the intervention, there was no difference in HF readmissions (28% vs. 25%, p=0.72), all-cause mortality (14% vs. 17%, p=0.64) and quality of life (1.7+/-0.9 vs. 1.8+/-1, p=0.24) between the groups. Survival and the probability of not being readmitted due to HF were similar in both groups. There was also a reduction in the use of beta-blockers and spironolactone in the intervention group.
The positive effects of an intervention programme are clearly reduced when it is stopped, due to less strict control of the patients and a decrease in the use of drugs with proven efficacy in HF.
本研究的目的是评估在干预计划停止后,该计划期间所取得的改善是否得以维持。153例诊断为心力衰竭(HF)的出院患者被随机分为常规治疗组或干预计划组,干预计划包括患者教育、与心脏病专家会诊以及在心力衰竭病房进行监测。平均16±8个月后,干预计划停止。一年后,对所有患者进行复查,以评估心力衰竭再入院情况、全因死亡率、生活质量和处方药物治疗情况。在16±8个月的治疗期间,干预组患者的心力衰竭再入院率较低(17%对51%,p<0.01),全因死亡率较低(13%对27%,p=0.03),生活质量有所改善(1.5±0.8对1.9±1,p=0.03),并且实现了药物治疗的优化。干预停止一年后,两组在心力衰竭再入院率(28%对25%,p=0.72)、全因死亡率(14%对17%,p=0.64)和生活质量(1.7±0.9对1.8±1,p=0.24)方面没有差异。两组的生存率和因心力衰竭未再入院的概率相似。干预组中β受体阻滞剂和螺内酯的使用也有所减少。
由于对患者的控制不那么严格以及心力衰竭中已证实有效的药物使用减少,干预计划停止后其积极效果明显降低。